Revista Brasileira de Hematologia e Hemoterapia
Print version ISSN 1516-8484
BERNARDI, Patrícia S. M. and MOREIRA, Haroldo W.. Analysis of the waves and aggregation patterns in patients with cardiovascular diseases in using acetylsalicylic acid compared blood donors. Rev. Bras. Hematol. Hemoter. [online]. 2004, vol.26, n.4, pp. 239-244. ISSN 1516-8484. http://dx.doi.org/10.1590/S1516-84842004000400003.
Platelet aggregation illustrates the function of the platelets by different ways of in vitro platelet activation providing wave traces equivalent to the physical proprieties of this aggregation. It is well known that aspirin irreversibly blocks the cyclooxygenase enzyme preventing the release of thromboxane A2, a potent activator of platelet aggregation. This drug has been evaluated for more than thirty years as a potent antithrombotic drug in patients with cardiovascular diseases. Our objective was to obtain wave traces corresponding to platelet aggregation phases for standardization purposes using blood donors as a control group and comparing the results with a study group using different agonistic agents at different concentrations: ADP 1 µM and 3 µM; AA 0.5 mM and ADR at 0.05 mg/mL, 0.025 mg/mL and 0.010 mg/mL. The analyzed groups were composed of 41 cardiac patients and 40 blood donors. Among the cardiac patients, 33 regularly used 200 mg of ASA per day and 8 patients normally used 100 mg of ASA per day, all of whom were considered hypertensive. The pattern of aggregation was dependent on conjunction traces corresponding to aggregation waves. A percentage at 5 minutes was obtained with these traces established by the equipment used. In our work, comparing the results among analysed patients and the control group, it was possible to observe that in the presence of the aggregating agents ADP 1µM and ADP 3µM; ADR 0.05 mg/mL, 0.025 mg/mL and 0.010 mg/mL the patients showed the first wave but no second wave aggregation. However, in respect to AA 0.5 mM the conjunction of the trace waves was not seen.
Keywords : Phases of platelet aggregation; acetylsalicylic acid; cardiovascular diseases.